QVentures Participates in Congenica’s £39m Series C Funding Round
QVentures is thrilled to welcome Congenica, one of Britain’s fastest-growing genomics companies, into their portfolio.
QVentures was engaged by Congenica to broaden access to its Series C funding round to Family Offices and sophisticated high net worth individuals. The QVentures investment followed the initial close of the round in November 2020, which raised US$50m/£39m and was led by Legal & General and Tencent, alongside investors such as Parkwalk, Cambridge Innovation Capital, Downing, Xeraya, Puhua Capital, and IDO Investments.
Congenica is pioneering the genomic study of rare diseases and inherited cancer and has developed a software enabling data analysis 20x faster than industry averages. Guided by a mission to make personalised medicine a routine part of healthcare, Congenica has developed sophisticated software and data systems designed to interpret complex genomic data.
The Cambridge-based company has received outstanding global reach, having established a diverse, customer-base of hospitals, diagnostic laboratories, academic medical centres, and pharmaceutical companies spanning 19 countries across Europe, North America, Asia, and the Middle East.
Robert Walsh, Managing Partner at QVentures says, “We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates and we believe David and his team are doing just that. We are pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey.”
QVentures is proud to have supported a company which has the potential to improve the lives of millions by fully integrating genomics into healthcare so that personalised decisions and treatments, guided by genomic information, can be routinely used to improve health and wellness around the world.
QVentures is a Venture Capital firm providing direct investment opportunities and fund management. QVentures sources, screens, and invests in top-tier start-ups from Seed to Series B for their investor base consisting of Family Offices, Institutional Investors, UHNWIs, and Cashed-out Entrepreneurs. QVentures has participated in rounds totalling £220m across 115 companies.
If you are looking to invest in early-stage companies, request information about membership to email@example.com
If you are seeking funding, please apply on www.qventures.co/fundraising
Investing in early-stage businesses involves risks, including illiquidity (the inability to sell assets quickly or without substantial loss in value), lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio.
QVentures is a trading name of Quintessentially Ventures Limited, which is an Appointed Representative of Brooklands Fund Management Limited which is authorised and regulated by the Financial Conduct Authority (FRN 757575).